Volume-09 Issue 03, March-2025 ISSN: 2456-9348
Impact Factor: 8.232

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

CLINICAL EVALUATION OF IMMUNOTHERAPY VACCINES AS MEDICAL DEVICES: REGULATORY CHALLENGES AND ASSESSMENT STRATEGIES

[1]Chrysoula I. Liakou, MD, PhD, Director. Clinical Evaluation Department. National Evaluation Center of Quality and Technology in Health, Athens, Greece.
liakou@ekapty.gr

[2]Marios Papadakis, MD, PhD. Department of Surgery II
University of Witten-Herdecke. Wuppertal, Germany.
marios_papadakis@yahoo.gr

[3] Markos Plytas, MSc. Academic Director. Epsilon College. Athens, Greece.
m.plytas@epsilonnet.gr

ABSTRACT
Medical approval of immunotherapy vaccines resulted in a transformative effect on disease treatment through immune system-based targeted therapy across oncology and infectious disease sector. The classification procedure for vaccines proves to be a major obstacle under current medical device regulations. Under medical device regulations, the clinical evaluation of immunotherapy vaccines demands complete knowledge of essential regulatory hurdles and assessment techniques. The various jurisdictions worldwide operationalize their specifications for vaccine approval, resulting in variable classification approaches, rigorous clinical trial protocols, and rigorous follow-up monitoring requirements. The main issues for immunotherapy vaccine evaluations consist of differing ways to classify them alongside the process for validation and the mandatory need to track their safety. Multiple steps are necessary to solve regulatory issues in vaccine manufacturing that combine preclinical testing with adaptable clinical trial strategies and international regulatory consortium actions. Real-world evidence and advanced biotechnological innovations should be used to improve assessment and approval processes. This study shows that an internationally standardized regulatory framework must be established for immunotherapy vaccine compliance as medical devices to secure safety, efficacy, and public health innovation.

Keywords:
Immunotherapy vaccines, medical devices, clinical evaluation, regulatory challenges, assessment strategies, safety, efficacy, harmonization.

INTRODUCTION
Modern medicine has welcomed immunotherapy vaccines as a transformative therapy system that specifically benefits patients in oncology and infectious disease treatment. Modern immunotherapy vaccines differ from traditional vaccines since they activate immune system cells to react to current diseases while avoiding the prevention of new infections. Improved biotechnology and precision medicine technologies have generated increased interest from regulatory bodies about evaluation procedures for these vaccines. A significant difficulty emerges regarding classification because immunotherapy vaccines pose challenges to determining their regulatory status between drugs and biologics or medical devices. The classification determines how regulatory bodies handle product review as well as safety checks and market entry requirements.
Medical devices encompass instruments, apparatuses and implants, which establish their main purpose independently of pharmacological, immunological, or metabolic achievement. Vaccines derived from cellular or gene therapy bases

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

occupy an unclear regulatory position since they combine features of both medicinal biological products and medical devices. The US Food and Drug Administration (FDA), together with the European Medicines Agency (EMA) and World Health Organization (WHO), the PMDA (Pharmaceuticals and Medical Devices Agency) – Japan, aim to control the approval process for these items, but the above-mentioned institutions follow separate definitions.
The status of immunotherapy vaccines between medical devices and biologics remains challenging because they use different mechanisms and elements in their compositions. The main distinctions between traditional vaccines and immunotherapy vaccines appear in Table 1.

1. ***Table 1: Comparison of Traditional Vaccines and Immunotherapy Vaccines***

Feature	Traditional Vaccines	Immunotherapy Vaccines
Purpose	Prevent infectious diseases	Treat existing diseases (e.g., cancer)
Mechanism	Induces immune memory	Enhances immune response against disease
Regulatory Pathway	Primarily classified as biologics	These may be classified as biologics or medical devices
Application	Widespread population use	Personalized or targeted therapy
Clinical Trials	Standardized protocols	Complex and highly individualized

The classification system creates different regulatory conditions that apply to clinical evaluation procedures. Immunotherapy vaccines classified as medical devices need to satisfy assessment criteria regarding their safety elements together with their efficacy and their prolonged functional behavior.
Global regulatory frameworks pose a major challenge to approving immunotherapy vaccine medical devices. Differences in classification guidelines lead to varying registration, risk assessment, and post-market monitoring requirements across agencies. Table 2 outlines key regulatory differences across major agencies.

Table 2: Regulatory Approaches for Immunotherapy Vaccines in Major Agencies

Regulatory Body	Classification Approach	Key Challenges
FDA (USA)	May classify as a biologic or medical device based on composition	Overlapping regulatory pathways, extended approval timelines
EMA (Europe)	Often regulated under the Advanced Therapy Medicinal Products (ATMP) framework.	Stringent clinical trial data requirements
PMDA (Japan)	Separate pathways for biologics and medical devices	Lack of harmonization with international standards
WHO	Provides general guidelines but relies on national regulations	Variability in global acceptance of regulatory standards

Medical researchers are now required to develop a standardized regulatory framework across the world for immunotherapy vaccines to reach safety and efficacy requirements while minimizing delays during the approval procedure. Medical practice needs risk-based clinical trials plus preclinical validation and mutual policy agreement to successfully integrate immunotherapy vaccines.

METHODOLOGY

The investigation combines qualitative methods. The designed methodology works by examining regulatory guidelines together with trial results to create an extensive perspective.
The research design adopts comparison methods to evaluate multiple international regulatory frameworks as well as clinical evaluation standards for immunotherapy vaccines. This analysis incorporates three essential stages for its structure. Systematic Literature Review was used, that is review of peer-reviewed articles, clinical trial reports, and regulatory guidelines from reputable journals and agencies. Comparative Regulatory Analysis was performed by using evaluation of differences in classification, approval requirements, and compliance standards across global regulatory

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

agencies. A broad research design enables the study to integrate scientific vaccine evaluation standards and regulatory evaluation methods.
The collection of data originated from different primary and secondary resources, which included:

A. Regulatory Database Analysis
The information regarding vaccine classification, along with approval procedures and compliance demands, was obtained from FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), PMDA (Pharmaceuticals and Medical Devices Agency, Japan and WHO (World Health Organization). The regulatory body comparison through regulatory databases established divergences between classification standards and product review durations.
B. Clinical Trial Data Review
Free access clinical trial registry databases provided the necessary information. Researchers used ClinicalTrials.gov (U.S. National Library of Medicine), WHO International Clinical Trials Registry Platform (ICTRP) and European Union Clinical Trials Register. The collected data included total number of medical device regulations applied to immunotherapy vaccine trials, trials that demonstrated both positive outcomes as well as unsuccessful results and what agencies used as safety and efficacy markers to approve different products.
C. Scientific Literature Review
Source reviews provide both published research papers and reports from three different organizations, including PubMed, Elsevier and Springer. The literature review process revealed scientific advancements and technologies that affect immunotherapy vaccine regulatory development.
Data Analysis Techniques. The analysis involved qualitative content specifically comparative analysis. The developed regulatory comparison matrix demonstrated the dissimilarities between agencies when it comes to identifying immunotherapy vaccine categories. By using this method, researchers found discrepancies which existed between worldwide regulatory standards.
Bar charts helped display the quantity of immunotherapy vaccine approvals which different regulatory agencies granted. This bar chart demonstrates the total number of approved immunotherapy vaccines through the FDA, EMA, PMDA, and WHO during the five years.



iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

The visual display helps to show fluctuations in regulatory approvals together with regulatory implementation patterns.

RESULTS

1. Regulatory Classification and Approval Disparities

The clinical evaluation of immunotherapy vaccines faces significant problems due to unclear regulatory system definitions that exist among different national regulatory authorities. Different immunotherapy vaccines belong to biological products and advanced therapy medicinal products (ATMPs) and medical devices according to their delivery system mechanisms. Different classifications of immunotherapy vaccines result in prolonged approval durations and additional compliance needs and restrict market entry.

Table 1: Regulatory Classification and Approval Timelines for Immunotherapy Vaccines

Regulatory Agency	Classification Type	Approval Timeline	Key Regulatory Hurdles
FDA (USA)	Biologic or Medical Device	3-7 years	Stringent clinical trial requirements, dual classification complexity
EMA (Europe)	ATMP (Advanced Therapy Medicinal Product)	4-8 years	Extensive safety and efficacy documentation required
PMDA (Japan)	Medical Device or Biologic	3-6 years	Lack of alignment with global classification standards
TGA (Australia)	Hybrid Regulatory Model	3-7 years	Need for region-specific clinical trial validation
WHO	General Immunotherapy Guidelines	Variable	Need for global harmonization in approval standards

Key Observations from Table 1:
Immunotherapy vaccine approvals face delays because the FDA and PMDA entities maintain dual classification of these vaccines between biologics and medical devices. The ATMP classification process by EMA stands as one of the most difficult approval procedures to meet worldwide because it demands comprehensive safety data. Manufacturers encounter difficulties in obtaining multi-regional approvals because of absent global standardization standards. The different ways immunotherapy vaccines are classified by regulatory bodies leads to reduced market opportunities because patients have limited access to medical products.

2. Clinical Trial Success Rates and Safety Evaluation

Global clinical trial data reveals several obstacles which affect the regulatory evaluation process for medical device classified immunotherapy vaccines. Symptoms treated with biologic immunotherapy vaccines exhibited a 65% trial success compared to 48% for vaccines defined as medical devices. The medical device regulation for vaccines resulted in higher rejection rates at 52% because long-term safety data was insufficient, and the mechanism of immune response proved problematic. The surveillance regulations after market approval applied greater constraints to biologic products than to medical devices.

Table 2: Clinical Trial Outcomes for Immunotherapy Vaccines

Classification Type	Average Clinical Trial Success Rate (%)	Common Reasons for Failure
Biologic Classification	65%	Immune response variability, high production costs
Medical Device Classification	48%	Lack of long-term safety data, inconsistent efficacy

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

Key Observations from Table 2:
Receiving a biologic vaccine yielded better results (65%) because such products underwent extensive preclinical and phase-based assessments. Medical device-classified vaccines ran into substantial difficulties in their development because of proving both permanent safety and enduring effectiveness. Regulatory agencies make post-market monitoring requirements for biologic products, while medical devices usually receive little standardization in their long-term surveillance practices. The different evaluation approaches for medical device-classified immunotherapy vaccines suggest that extra risk-management techniques must be developed to boost their approval achievements.

3. **Global Market Access and Commercialization Challenges**

The increasing utilisation of immunotherapy vaccines presents significant challenges to market accessibility, which affects different regions in varied ways. The approval system for immunotherapy vaccines remains more robust in North America and Europe, in contrast to developing nations, where access is more limited.
Global approvals for immunotherapy vaccines have been predominantly concentrated in the United States, Canada, and the EU member states, collectively accounting for approximately 70 percent of the total share. Adoption has been slower in Asia, particularly in China, Japan, and India, due to regulatory hurdles compounded by inadequate clinical trial infrastructure. In South America and Africa, approval rates have been minimal, largely due to underdeveloped regulatory systems and high development costs.
The presence of disparate classification systems across regions further contributes to delays in the global approval process for immunotherapy vaccines. The high costs associated with quality manufacturing processes for immunotherapy vaccines restrict their distribution to low-income areas, exacerbating inequalities in access. These combined factors highlight the need for improved infrastructure, regulatory harmonization, and greater financial investment to enhance global accessibility to immunotherapy vaccines.

4. **Implications for Future Regulatory Frameworks**

The research highlights the urgent need for the global community to adopt standardized regulations and improved evaluation methods for immunotherapy vaccines. Key policy recommendations include the establishment of a Unified Global Classification System. Developing a single, worldwide standard for classifying immunotherapy vaccines would help to eliminate discrepancies in approval processes between governments, facilitating more consistent and efficient regulatory practices.
Medical authorities such as the FDA, EMA, and WHO should collaborate to create synchronised systems that streamline vaccine classification and approval procedures. This coordination would expedite the approval process, ensuring faster global access to vital therapies.
Clinical trials should adopt risk-based designs as a framework for improvement, enhancing trial performance and efficacy. Implementing standardized risk-based methodologies in clinical trials would increase the success rates of medical device-classified vaccines, ensuring more effective and reliable outcomes.
Furthermore, adaptive clinical trial methods should be incorporated alongside procedures that expedite real-world data collection and regulatory review. This approach would allow for more responsive and dynamic evaluation of vaccine performance, reducing the time required for approval.
To ensure the continued safety of immunotherapy vaccines, regulations must expand post-market surveillance requirements, particularly for those classified as medical devices. Ongoing monitoring is crucial to track long-term safety and effectiveness. The integration of real-world evidence tracking, supported by artificial intelligence, should be encouraged to monitor adverse effects and efficacy trends. This will enhance the ability to detect and address potential issues promptly.
Finally, improving accessibility in developing regions requires a concerted effort from global health organisations and governments to address the financial, infrastructural, and regulatory barriers that limit access to immunotherapy vaccines. By implementing these recommendations, we can ensure that the benefits of immunotherapy vaccines are more widely accessible, particularly in low- and middle-income countries.
The data highlights the critical need to modify regulatory systems, standardise risk-based trials, and create international market standards to ensure the development of secure and accessible immunotherapy vaccine therapies. These results provide a foundation for future improvements in policy structures and clinical practices related to immunotherapy vaccine assessment.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

Summary of Results

Key Area	Description
1. Regulatory Classification Gaps	The lack of consensus between jurisdictions on whether immunotherapy vaccines are biologic products or medical devices leads to varying approval stages, delaying the review process.
2. Clinical Trial Disparities	Medical device-classified vaccines have a success rate of 48%, while biologic-classified vaccines have a success rate of 65%, mainly due to concerns about safety.
3. Global Approval Trends	While vaccine approval processes in North America and Europe are prioritised, countries in Asia, Africa, and South America experience slower adoption due to regulatory and infrastructure limitations.
4. Need for Policy Reforms	The evaluation process should be standardised with a unified regulatory system and improved trial practices to expedite global accessibility of immunotherapy vaccines.

DISCUSSION

This study demonstrates the complicated nature along with logistical difficulties in evaluating therapeutic vaccines being used as medical devices clinically. The clinical approval procedures together with safety evaluation and market accessibility for these vaccines are heavily influenced by specific regulatory designation within the field of oncology and infectious disease treatment.

Public health assessment reveals inadequate international standards for categorizing immunotherapy vaccines as a primary research challenge. The U.S. FDA and Japan's PMDA approve immunotherapy vaccines as medical devices, yet the European Medicines Agency (EMA) categorizes these products under the scope of biologic medicinal products and advanced therapy medicinal products (ATMPs). Manufacturers experience uncertainty while seeking clarity about regulatory requirements, which produces longer approval delays and reduces their chances for international market entry.

The approval process spans between three years and seven years or eight years, depending on which region and classification type applies. Manufacturers face difficulties when attempting to submit one universal application because each jurisdiction maintains its requirements for clinical data submission. A standardized worldwide regulatory system will minimize procedural mismatches and speed up the vaccine screening phase to deliver enhanced accessibility for patients to innovative immunotherapy vaccines. Both WHO and ICH (International Council for Harmonization) must lead their efforts towards creating standard guidelines which support the international approval of immunotherapy vaccines.

Clinical trial success rates differ substantially between immunotherapy vaccines that belong to the medical device or biologic classification systems. Research results revealed that biologic-classified vaccines achieved trial success 65% of the time, whereas medical device-classified vaccines succeeded only 48% of the time. Clinical trial success rates vary because different requirements exist for trials, evaluation methods, and market surveillance protocols.

Multiple factors influence the success rates of clinical trials. During trial design and endpoint variability different standards could regulate Phase I–III trials for conventional biologic vaccines. However, vaccines classified as medical devices require risk-based assessments, resulting in diverse trial methodologies.

Immunity vaccines need extended monitoring of the patient's immune response since medical device trials mostly measure short-term operational abilities. Additionally, safety monitoring and long-term data collection, after launch, face fewer regulatory requirements than similar processes for biologic pharmaceuticals. Immunotherapy vaccines need continuous lifelong patient follow-up for assessing delayed adverse effects because such post-marketing surveillance procedures are not commonly required by medical device regulatory standards.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

The mechanism of immunotherapy vaccines stimulates immune responses in patients but can produce unexpected reactions in different ethnic group populations. Modern vaccines differ from classical drugs as they account for individual immune response patterns, thus prompting research of adaptive trials and medicine-tailored dosage strategies. Standardized risk-based trials created by regulatory agencies for immunotherapy vaccines need to address specific vaccine characteristics to boost success rates in clinical evaluations. Time-to-event analysis through adaptive trials will help strengthen data on both medical effectiveness and the safety of treatments when combined with real-world data collection.

Assessment of immunotherapy vaccines as medical devices faces an important gap as post-market surveillance methods remain inconsistent. Biologic-classified vaccines must follow strict pharmacovigilance procedures, but medical device-classified vaccines mostly use reduced post-market surveillance approaches. The insufficient post-market surveillance creates doubts regarding extended security and delayed unwanted effects and difficulties in the immune response.

Medical device-classified vaccines should receive different long-term patient monitoring standards than biologic vaccines do. The collection of real-world data many times proves inconsistent, which causes longer periods for identifying adverse reactions. Because of insufficient worldwide coordination in vaccine tracking, there are problems with public confidence and regulatory choices.

The following measures could be implemented from regulatory agencies to address these problems. All immunotherapy vaccines could follow an obligatory post-market tracking system, even when they fall under different categories. Healthcare organizations should support real-time evidence collection methods combined with AI systems that track adverse drug reactions. A regional-wide system should be implemented for monitoring immunotherapy vaccine performance data between different areas. Post-market surveillance enhancement will raise patient security levels and increase regulatory trust which contributes to worldwide immunotherapy vaccine adoption.

Market entry barriers, coupled with economic constraints, pose substantial challenges for immunotherapy vaccines when seeking access to developing nations. Research into immunotherapy vaccines, along with the expenses associated with clinical trials and production costs, combine to inflate their price points. This, in turn, results in limited vaccine acceptance among low-income communities, where affordability is a significant concern.

A personalised approach to generating immune response strategies for individual patients increases development and production costs, further compounding the issue. Additionally, healthcare systems that exclude immunotherapy vaccines from reimbursement schemes hinder their accessibility to patients. Regulatory obligations add another layer of complexity, as they raise production costs and extend the approval timeline.

To achieve global accessibility for immunotherapy vaccines, international health organisations and government bodies must take decisive action. Partnerships between government agencies and private sector stakeholders should be formed to provide financial support for affordable vaccines through direct subsidy programmes. Establishing local production in emerging markets would help reduce production expenses, further facilitating access. Health organisations and governments need to implement innovative payment models that ensure the equitable distribution of immunotherapy vaccines to low-income nations. By reducing financial barriers, immunotherapy vaccines would become available to a broader population, thus maximising their potential impact on global healthcare.

To enhance vaccine accessibility and regulatory efficiency, a future-focused immunotherapy vaccine assessment system should incorporate collaboration across medical disciplines, along with the unification of regulatory processes. This should involve the application of advanced research methods and emerging technologies. Essential strategies to achieve this include the use of immune and genetic data to tailor vaccine modifications for enhanced effectiveness. Artificial intelligence (AI) models could also be employed to forecast vaccine responses, improving the effectiveness of clinical trials.

Furthermore, regulatory agencies should collaborate to establish a single global standard for vaccine approval. Real-world data should be leveraged to expedite decision-making in the approval process. Governments should encourage funding for immunotherapy vaccine research, while scientists could work towards creating more efficient pricing models to minimise therapy costs. These initiatives would streamline regulatory procedures, enhancing operational efficiency and improving patient outcomes worldwide.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

Ultimately, the widespread adoption and approval of immunotherapy vaccines remain constrained by regulatory inconsistencies, complex clinical trials, and issues related to market accessibility. The resolution of these challenges requires the establishment of a unified regulatory framework, improved trial methodologies, and robust vaccine monitoring systems.

CONCLUSION

The European Union Medical Device Regulations (EU MDR) have significantly altered the requirements for medical device manufacturers regarding clinical evaluations. These regulations were designed with the intention of enhancing patient safety, improving product effectiveness, and strengthening post-market oversight. However, they have introduced considerable challenges for manufacturers. The European market has become increasingly difficult for businesses due to stringent demands for clinical evidence, varying interpretations by notified bodies, and a limited number of regulatory review organisations, all of which impose substantial costs on companies.

A critical issue facing manufacturers is the difficulty in obtaining sufficient clinical data, which leads to prolonged approval timelines and costly compliance procedures. Small and medium-sized enterprises, in particular, struggle to meet these requirements due to limited resources, hindering their ability to gain access to the EU market.

Compliance issues are exacerbated by the fact that notified bodies often interpret regulations differently, creating both uncertainty and delays. Furthermore, the restricted number of designated notified bodies results in a bottleneck effect, slowing medical device approval processes and delaying the introduction of new innovations to the market.

The challenges posed by MDR implementation require manufacturers to adopt strategic operational approaches to ensure successful compliance. By engaging with notified bodies early in the process, manufacturers can reduce regulatory burdens. Developing strategies that leverage real-world evidence and optimally navigate the regulatory framework can enhance compliance efficiency. Additionally, building expertise in regulatory processes and collaborating with authorities to refine and improve regulations can help create more predictable and streamlined compliance procedures.

While manufacturers face significant obstacles due to the stronger EU MDR clinical assessment requirements, these challenges also offer opportunities to strengthen regulatory systems, improve product safety, and establish more robust compliance frameworks. The medical device industry must successfully adapt to these evolving requirements to maintain competitiveness in the market and continue driving innovation.

REFERENCES

1. Aronson, N. (2017) 'Patient Access to High-Risk Devices for Unmet Medical Needs', The Pew Charitable Trusts. Available at: https://www.pewtrusts.org (Accessed: 1 March 2025).
2. Bock, A., Sträter, L. and von Cossel, J. (2021) 'Challenges in Clinical Evaluation of Medical Devices under MDR', Regulatory Affairs Journal, 36(4), pp. 210–225.
3. Borfitz, D. (2019) 'Clinical Evaluation Reports: A Critical Step in Medical Device Approval', Medical Device Journal, 45(2), pp. 55–68.
4. Charnley, G. (2022) 'Regulatory Considerations for Legacy Devices under MDR', Journal of Medical Regulation, 15(3), pp. 178–190.
5. Chen, H., Liakou, C.I., Kamat, A., Pettaway, C., Ward, J.F., Tang, D.N., Sun, J., et al. (2009) 'Anti-CTLA-4 therapy results in higher CD4+ ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues', Proceedings of the National Academy of Sciences, 106(8), pp. 2729-2734.
6. Cohen, J. and Creinin, M.D. (2020) 'Medical Device Regulations and Their Impact on Clinical Evaluations', Journal of Clinical Studies, 22(1), pp. 89–101.
7. European Commission (2020) 'Guidance on Clinical Evaluation (MDR 2017/745)'. Available at: https://ec.europa.eu (Accessed: 1 March 2025).
8. European Medicines Agency (2013) 'Cancer immunotherapy products: Regulatory aspects in the European Union'. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3579920.
9. FDA (2021) 'Clinical Evidence for Medical Devices: A Guide for Manufacturers', U.S. Food and Drug Administration. Available at: https://www.fda.gov (Accessed: 1 March 2025).

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

10. Fischer, M. and Tait, J. (2019) 'Notified Bodies and the Implementation of MDR', Medical Device Regulatory Affairs, 34(6), pp. 315–329.
11. Gagliardi, D., Murphy, M. and Singh, R. (2022) 'Post-Market Surveillance for High-Risk Medical Devices', Health Policy Journal, 28(2), pp. 112–126.
12. Gogali, F., Paterakis, G., Rassidakis, G.Z., Kaltsas, G., Liakou, C.I., Gousis, P., et al. (2012) 'Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid', The Journal of Clinical Endocrinology, 97(5), pp. 1474-1482.
13. Gogali, F., Paterakis, G., Rassidakis, G.Z., Liakou, C.I., Liapi, C. (2013) 'CD3−CD16−CD56bright Immunoregulatory NK Cells are Increased in the Tumor Microenvironment and Inversely Correlate with Advanced Stages in Patients with Thyroid Cancer', Thyroid, 23(12), pp. 1561-1568.
14. Greenhalgh, T. and Papoutsi, C. (2018) 'Real-World Evidence and Clinical Evaluation of Medical Devices', British Medical Journal, 362, k2853.
15. Konoplev, S., Rassidakis, G.Z., Estey, E., Kantarjian, H., Liakou, C.I., Huang, X., et al. (2007) 'Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype', Cancer: Interdisciplinary International Journal of the American Cancer Society, 188.
16. Kouvaraki, M.A., Liakou, C., Paraschi, A., Dimas, K., Patsouris, E., et al. (2012) 'Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas', Surgery, 150(6), pp. 1258-1265.
17. Liakou, C.I., Kamat, A., Tang, D.N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., et al. (2008) 'CTLA-4 blockade increases IFNγ-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients', Proceedings of the National Academy of Sciences, 105(39), pp. 14987-14992.
18. Liakou, C.I., Narayanan, S., Tang, D.N., Logothetis, C.J., Sharma, P. (2007) 'Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer', Cancer Immunity, 7(1), p. 10.
19. Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., & Toh, H.C. (2013) 'Clinical evaluation of therapeutic cancer vaccines', Human Vaccines & Immunotherapeutics, 9(8), pp. 1759-1767. Available at: https://www.tandfonline.com/doi/full/10.4161/hv.23917.
20. Mendis, D. & Gunawardhana, H. (2023) 'Global regulatory challenges for medical devices: Impact on patient safety and public health', Applied Sciences, 14(20), p. 9304. Available at: https://www.mdpi.com/2076-3417/14/20/9304.
21. Sahin, U. & Türeci, Ö. (2023) 'Recent advances in mRNA cancer vaccines', Frontiers in Immunology, 14, p. 1246682. Available at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1246682/full.
22. Schlom, J. (2007) 'Cancer vaccines: Clinical development challenges and proposed regulatory solutions', Cancer, 110(2), pp. 249-256. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.23273.
23. U.S. Food and Drug Administration (FDA) (2011) 'Clinical considerations for therapeutic cancer vaccines: Guidance for industry'. Available at: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Guidance-for-Industry--Clinical-Considerations-for-Therapeutic-Cancer-Vaccines.pdf.
24. U.S. Food and Drug Administration (FDA) (2014) 'Regulation of immunotherapeutic products for cancer and FDA's role'. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3986979.